In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, discussed the patient-site relationship, the role of technology in clinical trial delivery ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale. AI adoption is moving quickly in life sciences, ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are ...
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has ...
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol ...
In this Q&A, Patrick Mizer, chief technology officer at Ledger Run, discusses how payment reliability has become a ...
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination ...
True lab orchestration isn't about coordinating instruments, it's about connecting scientific intent, data, and decisions ...
In today's ACT Brief, we examine value hidden in the RBQM financial model, why rare disease research leads on genuine patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results